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Abstract
Facilitating clinical translation of quantitative imaging techniques has been suggested as
means of improving interobserver agreement and diagnostic accuracy of multiparametric
magnetic resonance imaging (mpMRI) of the prostate. One such technique, magnetic reso-
nance fingerprinting (MRF), has significant competitive advantages over conventional map-
ping techniques in terms of its multi-site reproducibility, short scanning time and inherent
robustness to motion. It has also been shown to improve the detection of clinically significant
prostate cancer when added to standard mpMRI sequences, however, the existing studies
have all been conducted on 3.0 T MRI systems, limiting the technique’s use on 1.5 T MRI
scanners that are still more widely used for prostate imaging across the globe. The aim of
this proof-of-concept study was, therefore, to evaluate the cross-system reproducibility of
prostate MRF T1 in healthy volunteers (HVs) using 1.5 and 3.0 T MRI systems. The initial
validation of MRF T1 against gold standard inversion recovery fast spin echo (IR-FSE) T1 in
the ISMRM/NIST MRI system revealed a strong linear correlation between phantom-derived
MRF and IR-FSE T1 values was observed at both field strengths (R
2 = 0.998 at 1.5T and R2
= 0.993 at 3T; p = < 0.0001 for both). In young HVs, inter-scanner CVs demonstrated mar-
ginal differences across all tissues with the highest difference of 3% observed in fat (2% at
1.5T vs 5% at 3T). At both field strengths, MRF T1 could confidently differentiate prostate
peripheral zone from transition zone, which highlights the high quantitative potential of the
technique given the known difficulty of tissue differentiation in this age group. The high
cross-system reproducibility of MRF T1 relaxometry of the healthy prostate observed in this
preliminary study, therefore, supports the technique’s prospective clinical validation as part
of larger trials employing 1.5 T MRI systems, which are still widely used clinically for routine
mpMRI of the prostate.
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Introduction
Multiparametric magnetic resonance imaging (mpMRI) has recently been adopted by major
European and American prostate cancer (PCa) guidelines as the key diagnostic tool for detec-
tion, local staging and active surveillance of the disease [1, 2]. Despite significant advantages
over the traditional systematic biopsy pathway, such as high negative predictive value for clini-
cally significant PCa, mpMRI has limitations including a known learning curve and consider-
able interobserver variation for image assessment, even amongst experience readers [3–8].
Making prostate MRI more objective by facilitating clinical translation of quantitative imaging
techniques is viewed by many experts as key to solving the aforementioned challenges [9, 10].
This move is also supported by the Prostate Imaging Reporting and Data System (PI-RADS)
steering committee with a view to complement the current recommendations that are based
exclusively on qualitative visual assessment of images [11, 12].
MR fingerprinting is a rapidly developing quantitative imaging technique enabling fast and
simultaneous generation of tissue T1 and T2 property maps that are inherently spatially regis-
tered and robust to motion [13, 14]. The key competitive advantages of MRF over standard
mapping techniques, which also make it attractive for PCa imaging, include its higher multi-
site reproducibility and significantly shorter acquisition time, which is important given the
current move towards developing abbreviated prostate imaging protocols in order to reduce
scanning times whilst maintaining quality [14–19].
Several pilot studies investigating the added value of MRF to prostate mpMRI have demon-
strated significantly improved detection of clinically significant peripheral zone (PZ) and tran-
sition zone (TZ) tumors when MRF was used in combination with apparent diffusion
coefficient (ADC) mapping [20–23]. However, wider clinical validation of MRF as part of an
mpMRI protocol is limited by the fact studies have only validated performance on 3T MRI sys-
tems, whist the majority of prostate mpMRI scans even in developed countries are still per-
formed on 1.5T scanners [24–27]. The most recent version of the PI-RADS guidelines (v2.1)
suggest that both 1.5T and 3T allow for reliable diagnostic exams in the context of adequate
hardware and software, and when optimal acquisition parameters are ensured. [10]
Whilst MRF at both 1.5T and 3T has been used in cardiac and brain imaging, there are sur-
prisingly few studies dedicated to cross-system validation of MRF in different body areas other
than the brain [28–30]. It is known that longitudinal T1 relaxation times are more sensitive to
an increase of the magnetic field strength compared to T2 relaxation and quantitative magneti-
sation transfer parameters [31]. In the prostate, which generally has longer T1 values compared
to other pelvic and abdominal organs, field-dependent variation of T1 can reach up to 24%,
which may affect the cross-system reproducibility of MRF [15, 32].
Therefore, the objective of this proof-of-concept study was to evaluate the cross-system
reproducibility of MRF-based T1 mapping of the healthy prostate with data acquired from
both phantoms and healthy volunteers using 1.5T and 3T MRI systems.
Methods
Phantom study
To evaluate the accuracy of the introduced T1 and T2 measurements, MRF and standard relax-
ation mapping data were obtained from the ISMRM/NIST phantom. [27] Phantom data were
obtained on 1.5T MR450 and 3T MR750w scanners (both GE Healthcare, Waukesha, WI,
USA) using a 32-channel receiver coil. Regions-of-interest (ROIs) were created from the
spheres in either the T1 or T2 layer of the phantom. MR Fingerprinting was performed as fur-
ther described in section 2.4.
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Conventional T1 and T2 mapping was performed with inversion recovery fast spin echo
(IR-FSE) and multiple spin echo (MSE) imaging, respectively. The field-of-view (FOV) =
260x260 mm2, matrix = 256x256 and slice thickness = 3 mm matched in all techniques. For 2D
IR-FSE T1 mapping, data were acquired with inversion times (TIs) of 50, 100, 200, 400, 800,
1600, and 2400 ms. The IR-FSE sequence used a repetition time (TR) = 8000 ms and echo time
(TE) = 13 ms at both 1.5 T and 3.0 T. T1 data for all non-MRF techniques were fit using non-
linear fitting of the signal equations in Python. Multiple spin echo (MSE) data for T2 estima-
tions were acquired with TEs = 8.1, 16.3, 24.4, 32.6, 40.7, 58.9, 57.0, 65.2 ms. MSE data were fit
with a log linear least squares algorithm. The acquisition matched the FOV, matrix, and slices
as the MRF acquisition.
Healthy volunteers study
All elements of this prospective study were carried out in accordance with the Declaration of
Helsinki and were approved by the institutional ethics board (NRES Committee East of
England, UK), with written informed consent obtained from all participants. The volunteers
were aged at least 18 years were included in this study, with the exclusion criteria being previ-
ous diagnosis or treatment for prostate cancer and clinical contraindication to MRI.
Anatomical imaging
Healthy volunteers underwent prostate MRI on the same 1.5T MR450 and 3T MR750 scanners
(both GE Healthcare, Waukesha, WI, USA) used in the phantom study. As per clinical
mpMRI acquisition, the protocol included Axial T1 and multiplanar high-resolution
T2-weighted 2D fast recovery FSE (FOV = 18x18 cm; voxel size 0.35x0.35 mm2; slice
thickness = 3–4 mm; gap = 0–0.5 mm). Diffusion-weighted imaging (DWI) was performed
using a spin-echo echo-planar imaging pulse sequence (FOV 28cm; slice thickness 3mm; gap
0mm; b-values: b-150, b-750, and b-1,400 s/mm2) and an additional small FOV (24 cm) b-
2,000s/mm2 DWI sequence; apparent diffusion coefficient (ADC) maps were calculated
automatically.
MR fingerprinting protocol
MRF at both 1.5 T and 3.0 T was acquired with an inversion-prepared 2D steady-state-free-
precession (SSFP) MRF sequence [13]. The acquisition consisted of 979 undersampled inter-
leaved spirals with 656 points per spiral, and with sequential spirals rotated by the golden
angle. The maximum gradient strength per spiral was 28 mT/m and the maximum slew rate
was 108 T/m/s. The imaging parameters were: field-of-view (FOV) = 260x260 mm2,
matrix = 256x256, slices = 3 for ISMRM/NIST imaging and 12–14 for in vivo imaging, in vivo
slice thickness = 6 mm and 3 mm at 1.5T and 3T, respectively, spacing = 5mm and 6mm at
1.5T and 3T (39 mm for both for ISMRM/NIST imaging), respectively, sampling bandwidth =
±250 kHz, slice dephasing = 8π, echo time (TE) = 2.5 ms, repetition time (TR) = 10 ms, acqui-
sition time = 9.79 seconds/slice. The flip angle lists matched those in Jiang et al. [33]. Axial
images were acquired to match the standard acquisition planes for other prostate image
assessments.
Image analysis
MRF T1 values for the whole prostate, peripheral zone (PZ), transition zone (TZ), internal
obturator muscle and adipose tissue in the ischioanal fossa were calculated from ROIs drawn
by a single fellowship-trained uro-radiologist using the open-source segmentation software
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ITK-SNAP [34]. ROIs were drawn using anatomical T2WI as reference and subsequently
transposed on to the MRF T1 with their size and location being matched to the appropriate
FOV parameters and anatomical position of the outlined structures using in-house software
developed within Python using the PyQtGraph and PyDicom libraries [35].
Statistics
In the phantom study, simple linear regression was used to evaluate the relationship between
T1 and T2 values obtained using IR-FSE, MSE and MRF mapping techniques with their agree-
ment assessed using Bland-Altman analysis. In the healthy volunteers study, the D’Agostino
and Pearson test was applied to assess the distribution of imaging values with their intergroup
comparison performed using either paired t-test or Wilcoxon matched-pairs signed rank test
as appropriate. Both in the phantom and healthy volunteers studies, the variation of imaging
values as a means of their cross-system reproducibility was evaluated using a coefficient of var-




Summary mean inter-scanner T1 and T2 values obtained from the corresponding ISMRM/
NIST phantom layers using MRF, inversion recovery fast spin echo (IR-FSE) and multiple
spin echo (MSE) imaging are presented in Table 1. Paired t-test showed no inter-scanner dif-
ferences between IR-FSE and MRF-based T1 phantom values (p = 0.795 and p = 0.102, respec-
tively). As a measure of reproducibility, coefficients of variations (CVs) were calculated and
are also presented in Table 1, showing inter-scanner differences of 0.17% and 2.57% for
IR-FSE and MRF T1, respectively. Inter-scanner T2 values obtained using MRF and MSE
imaging were, however, significantly different in both cases (p = 0.0002 and p = 0.0006, respec-
tively) with differences in their CVs reaching 0.10% and 7.66%, respectively.
Fig 1A and 1B show the mean ISMRM/NIST phantom MRF T1 values plotted against T1
values obtained using inversion recovery fast spin echo (IR-FSE) imaging at 1.5T and 3T,
respectively. The analysis showed a strong linear correlation between MRF and IR-FSE at both
field strengths (R2 = 0.998 at 1.5T and R2 = 0.993 at 3T; p =< 0.0001 for both) with slopes of
the linear fits and y-intercepts presented in the corresponding figures. The Bland-Altman anal-
ysis revealed good agreement between the two techniques at both 1.5T and 3T with the corre-
sponding mean bias and 95% limits of agreement (LOA) presented in Fig 1D and 1E,
respectively. When plotted against each other, MRF T1 values obtained at 1.5T and 3T also
demonstrated a strong linear correlation (R2 = 0.994; p< 0.0001) and acceptable agreement
Table 1. Summary ISMRM/NIST phantom T1 and T2 relaxation times and coefficients of variation obtained using inversion recovery fast spin echo (IR-FSE), multi-
ple spin echo (MSE) and magnetic resonance fingerprinting (MRF) at 1.5T and 3T systems.
Mean ± SD Coefficient of variation (%)
Sequence 1.5T 3T P 1.5T 3T
IR-FSE T1 616.1 ± 400.9 615.8 ± 401.8 0.7951 65.08 65.25
MRF T1 559.3 ± 402.2 544.1 ± 405.3 0.1019 71.91 74.48
MSE T2 137.8 ± 112.2 92.8 ± 82.7 0.0002 116.80 116.90
MRF T2 471.2 ± 550.2 95.6 ± 111.8 0.0006 81.46 89.12
SD = standard deviation.
https://doi.org/10.1371/journal.pone.0245970.t001
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(bias 15.19 ms, 95% LOA -48.11 ms to 78.49 ms) with corresponding plots presented in Fig 1C
and 1F, respectively.
The outcomes of a similar analysis comparing the MRF and multiple spin echo (MSE) T2
values obtained at 1.5T and 3T are presented in Fig 2. It is of note that T2 values obtained in
this study showed consistently poorer reproducibility as demonstrated by both linear regres-
sion and Bland-Altman analysis, prompting us to focus the following presentation and analysis
of the in vivo results on T1 relaxometry.
Healthy volunteers study
The study included 10 healthy male volunteers (mean age 32.3 years, range 24–41) who under-
went MRF of the prostate at 1.5T and 3T within the same imaging session.
Summary mean inter-scanner MRF T1 values and coefficients of variation (CVs) obtained
from the whole prostate, peripheral zone (PZ), transition zone (TZ), internal obturator muscle
and fat in the ischioanal fossa are presented in Table 2. As expected, 3T MRF T1 values were
significantly longer in all tissues compared to 1.5T MRF (P< 0.0001 for all). Inter-scanner
CVs demonstrated only marginal differences in all tissues with the highest difference of 3%
observed in fat (2% at 1.5T vs 5% at 3T). T1 values obtained from the PZ showed the highest
overall variation with CVs at 1.5T and 3T being 10.9% and 10.3%, respectively. The outcomes
of a similar analysis conducted for in vivo MRF T2 relaxometry is presented in S1 Table.
Albeit weaker than in the phantom experiment, a strong linear correlation was noted
between the combined in vivo 1.5T and 3T MRF T1 values obtained from all tissues included
in the analysis (R2 = 0.914; p< 0.0001); Fig 3A. Fig 3B illustrates the inter-scanner agreement
between MRF T1 relaxation times (bias 602.1 ms, 95% LOA 72.0 ms to 1132.0 ms) with only a
Fig 1. Linear regression plots (a-c) and Bland-Altman plots (d-f) comparing MRF T1 ISMRM/NIST phantom values with those obtained using IR-FSE at 3T (a, d) and
1.5T (b, e). An inter-scanner comparison of MRF T1 values is also presented (c, f). On Fig (d-f), dotted lines represent upper and lower 95% limits of agreement and bold
lines represent the mean biases with appropriate captions included. MRF = magnetic resonance fingerprinting, IR-FSE = inversion recovery fast spin echo,
SD = standard deviation.
https://doi.org/10.1371/journal.pone.0245970.g001
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single value being outside the 95% LOA. The outcomes of the Bland-Altman analysis for each
individual tissue are presented in Fig 4, with acceptable agreement noted for all tissues
included in the analysis. S2 and S3 Figs depict the outcomes of a similar analysis for MRF T2
relaxometry.
At both 1.5T and 3T, MRF T1 relaxometry enabled confident differentiation between the
whole prostate, PZ and TZ (Fig 5). It is of note that the difference between MRF T1 relaxation
times derived from PZ and TZ was slightly more prominent at 3T (24%) compared to 1.5T
(19%). S3 Fig demonstrates the outcomes of a similar comparison for MRF T2 relaxometry.
Discussion
This prospective proof-of-concept study investigated the cross-system reproducibility of SSFP
MRF T1 of the prostate in healthy volunteers who were scanned using 1.5T and 3T systems
Fig 2. Linear regression plots (a-c) and Bland-Altman plots (d-f) comparing MRF T2 ISMRM/NIST phantom values with those obtained using MSE at 3T (a, d) and
1.5T (b, e). An inter-scanner comparison of MRF T2 values is also presented (c, f). On Fig (d-f), dotted lines represent upper and lower 95% limits of agreement and bold
lines represent the mean biases with appropriate captions included. MRF = magnetic resonance fingerprinting, MSE = multiple spin echo, SD = standard deviation.
https://doi.org/10.1371/journal.pone.0245970.g002
Table 2. Summary MRF T1 relaxation times and coefficients of variation obtained at 1.5T and 3T from the whole prostate, peripheral zone, transition zone, internal
obturator muscle and fat from the ischioanal fossa.
Mean ± SD Coefficient of variation (%)
Tissue 1.5T 3T P 1.5T 3T
Prostate 1054.0 ± 80.1 1769.0 ± 112.7 < 0.0001 7.60 6.37
Peripheral zone 1202.0 ± 131.3 2041.0 ± 209.4 < 0.0001 10.93 10.26
Transition zone 968.8 ± 60.7 1552.0 ± 105.2 < 0.0001 6.26 6.78
Muscle 725.6 ± 23.8 1446.0 ± 73.95 < 0.0001 3.29 5.12
Fat 192.1 ± 3.8 345.1 ± 17.1 < 0.0001 1.99 4.96
SD = standard deviation.
https://doi.org/10.1371/journal.pone.0245970.t002
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with the same sequence parameters and reconstruction methods. The study was preceded by a
phantom experiment that confirmed high reliability of MRF T1 mapping used when validated
against IR-FSE imaging. The healthy volunteers study revealed acceptable inter-scanner agree-
ment and excellent reproducibility of MRF T1 relaxometry in all tissues. At 3T, the magnitude
of difference between MRF T1 obtained from the peripheral and transition zones of the pros-
tate was slightly higher than at 1.5T, being, however, within the limits of statistical significance
at both field strengths. These results, therefore, support further validation of prostate MRF at
1.5T as part of a standard-of-care mpMRI protocol.
To our knowledge, this is the first study to report MRF of the prostate performed at 1.5T,
which is still commonly used for routine prostate imaging [26]. The observed high cross-sys-
tem reproducibility of prostate MRF T1 is similar to that reported in the brain by Buonincontri
et al., suggesting the overall robustness of MRF to field-dependent variation of T1 [30]. Our 3T
MRF T1 values obtained from the healthy PZ and TZ are similar to those obtained in a patient
population by other authors (2247.0 ms ± 450 ms for PZ [22] and 1800 ms ± 150 ms for TZ
[20]) with subtle differences being expected due to the known age-related changes in histologi-
cal and imaging features of the prostate [36, 37]. The observed ability of MRF to differentiate
PZ and TZ in healthy volunteers at both 1.5T and 3T highlights MRF’s sensitivity to the under-
lying tissue organisation, which may be even more prominent in the older patients, in whom
even visual differentiation of the prostatic zones is much less challenging [36, 38].
These preliminary results pave the way for future studies investigating the diagnostic per-
formance of prostate MRF at 1.5T. It is known that prostate mpMRI at 1.5T is able to produce
T2-weighted images of comparable diagnostic quality, however, the key argument in favour of
3T imaging is its ability to achieve higher signal-to-noise and contrast-to-noise ratios for diffu-
sion-weighted imaging (DWI), which is the key sequence for PZ assessment, enabling DWI at
higher b-values [39–42]. If 1.5T MRF retains its added value to ADC mapping previously dem-
onstrated at 3T, it can potentially compensate for the inherent inferiority of DWI at 1.5T [20–
22]. Furthermore, MRF’s inherent robustness to motion may help further establish its role as
an auxiliary sequence to DWI, which is often degraded by motion artefact or rectal loading
[43–46]. Finally, the added value of quantitative MRI can be harnessed clinically in the active
surveillance setting where time-series change of tumour-derived relaxometry can serve as a
more objective means of tracking the disease progression [47].
Fig 3. Linear regression (a) and Bland-Altman (b) plots comparing in vivo MRF T1 values obtained from all tissues combined at 1.5T and 3T systems. On Fig (b),
dotted lines represent upper and lower 95% limits of agreement and bold lines represent the mean biases with appropriate captions included. MRF = magnetic
resonance fingerprinting, SD = standard deviation.
https://doi.org/10.1371/journal.pone.0245970.g003
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Fig 4. Bland-Altman plots comparing in vivo MRF T1 values obtained from the whole prostate (a), peripheral zone (b), transition zone (c), internal obturator muscle
(d) and fat in the ischioanal fossa (e) at 1.5T and 3T systems. Dotted lines represent upper and lower 95% limits of agreement and bold lines represent the mean biases
with appropriate captions included. MRF = magnetic resonance fingerprinting, SD = standard deviation.
https://doi.org/10.1371/journal.pone.0245970.g004
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Our study has some limitations. The healthy volunteers study population was a small cohort
of healthy volunteers of a younger age than typical patients with PCa. Although this may have
introduced age-related heterogeneity, the reported high cross-system reproducibility of MRF
is further complemented by its ability to differentiate normal PZ and TZ, which is considered
less straightforward in younger adults [48]. Furthermore, the inclusion of older adults would
limit our ability to sample healthy prostatic tissue due to high prevalence of benign conditions
such as benign prostatic hyperplasia and prostatitis, or even undiagnosed PCa in otherwise
healthy older men [49, 50]. To achieve comparable image quality, MRF at 1.5T was acquired
with higher slice thickness and gap than at 3T, however, this mirrors standard clinical practice
[51]. Having shown broadly similar results, MRF T2 mapping was unreliable in this study, and
stronger consideration will be given in future studies to methods increasing its signal-to-noise
ratio and improving the pattern matching algorithms.
In conclusion, the excellent reproducibility and high cross-system agreement of MRF T1
relaxometry of the healthy prostate observed in this preliminary study support the tech-
nique’s prospective clinical validation on 1.5T MRI systems. The reported findings could be
used to justify further investigations for incorporating MRF into clinical prostate MRI proto-
cols, larger population studies, and multi-site/multi-vendor investigations. If this method
can be translated into clinical practice and improve both the speed and diagnostic value of
imaging, it would add significant value given the current unprecedented demand on imaging
services.
Fig 5. Box-and-whiskers plots representing MRF T1 relaxation times obtained from the whole prostate,
peripheral zone (PZ) and transition zone (TZ) at 1.5T and 3T (left and right sides of the graph, respectively). Top
and bottom of boxes represent 25th and 75th percentiles of data, respectively; line in boxes represents the median value
and bars represent minimum and maximum values. MRF = magnetic resonance fingerprinting.
https://doi.org/10.1371/journal.pone.0245970.g005
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Supporting information
S1 Table. Summary MRF T2 relaxation times and coefficients of variation obtained at 1.5T
and 3T from the whole prostate, peripheral zone, transition zone, internal obturator mus-
cle and fat from the ischioanal fossa. SD = standard deviation.
(DOCX)
S1 Fig. Linear regression (a) and Bland-Altman (b) plots comparing in vivo MRF T2 values
obtained from all tissues combined at 1.5T and 3T systems. On Fig (b), dotted lines represent
upper and lower 95% limits of agreement and bold lines represent the mean biases with appro-
priate captions included. MRF = magnetic resonance fingerprinting, SD = standard deviation.
(TIF)
S2 Fig. Bland-Altman plots comparing in vivo MRF T2 values obtained from the whole pros-
tate (a), peripheral zone (b), transition zone (c), internal obturator muscle (d) and fat in the
ischioanal fossa (e) at 1.5T and 3T systems. Dotted lines represent upper and lower 95% limits
of agreement and bold lines represent the mean biases with appropriate captions included.
MRF = magnetic resonance fingerprinting, SD = standard deviation.
(TIF)
S3 Fig. Box-and-whiskers plots representing MRF T2 relaxation times obtained from the
whole prostate, peripheral zone (PZ) and transition zone (TZ) at 1.5T and 3T (left and
right sides of the graph, respectively). Top and bottom of boxes represent 25th and 75th per-
centiles of data, respectively; line in boxes represents the median value and bars represent min-
imum and maximum values. MRF = magnetic resonance fingerprinting.
(TIF)
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